• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: Pipeline of Alzheimer’s drugs ‘due for big victories’ in next 5 years

July 19, 2017 By Sarah Faulkner

There are twenty-seven Alzheimer’s drugs in late-stage clinical trials and eight candidates in Phase II programs that could launch in the next 5 years, according to an analysis presented this week at the Alzheimer’s Association International Conference.

“The Alzheimer’s disease pipeline, marred by decades of failures and underinvestment, is due for big victories,” UsAgainstAlzheimer’s co-founder & chairman George Vradenburg said in prepared remarks. “Thanks to growing investment from industry leaders, we remain cautiously optimistic that the current crop of late-stage Alzheimer’s innovations will bring much-needed solutions to families in the near future.”

There are 23 drugs in Phase II and III trials that target amyloid protein buildup in the brain and 28 compounds that target neurotransmitter activity, the group reported.

These numbers represent momentum, according to the analysis – an 18% increase in Phase II drugs this year compared to last year and a 7% increase in Phase III compounds.

In 2017, Phase III trials are slated to wrap for six of the drugs described in the group’s presentation.

Deaths from Alzheimer’s disease are on the rise, said a recent report from the CDC, and a new treatment for the debilitating neurological condition hasn’t won approval from the FDA since 2003.

“There is no silver bullet when it comes to treating Alzheimer’s,” David Morgan, a founding member of ResearchersAgainstAlzheimers, said. “The more we learn about the underlying Alzheimer’s pathology, the closer we get to a cure for a disease that is an enormous burden on patients, caregivers and global health systems.”

The group also voiced their concerns about patient access to these drugs once, or if, any of the products reach the market.

“Alzheimer’s is commonly misdiagnosed, and the United States suffers from a shortage of geriatricians – issues that will only grow as the Baby Boomer generation ages,” Vradenburg said. “Private- and public-sector leaders will need to work closely with insurers in the coming years to ensure patients have access to these drugs when they are available.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Neurological, Pharmaceuticals, Research & Development Tagged With: Centers for Disease Control & Prevention

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS